MIMEDX GROUP, INC. (MDXG)

MIMEDX is a company focused on helping clinicians heal chronic and other hard-to-heal wounds. It provides a portfolio of products for the wound care, burn, and surgical sectors of healthcare. Historically it focused solely on placental biologics. In 2024 it added animal-derived products (xenografts), and in 2025 and early 2026 it signed agreements with manufacturers of other wound care modalities to broaden its offering. It also pursues growth through acquisitions and internal research and development.

The portfolio consists of tissue allografts derived from human placental membrane, umbilical cord and placental disc, plus a bovine collagen xenograft. The wound products include EPIFIX, EPICORD, EPICORD Expandable and EPIEFFECT. AMNIOEFFECT and AMNIOFIX are positioned for surgical applications, and AXIOFILL is positioned for replacing or supplementing damaged integumental tissue. In 2024 the company launched HELIOGEN Fibrillar Collagen Matrix, its first FDA 510(k)-cleared product, which is made by Regenity Biosciences. It also holds exclusive distribution agreements for RegenKit-Wound Gel, NovaForm Wound Matrix, G4Derm Plus and Hydrelix Collagen Matrix, and launched EPIXPRESS in late 2025. Its strategic priorities are to diversify its portfolio, expand its surgical footprint, and deepen customer relationships, including through MIMEDX Connect, an online ordering and account portal launched in March 2024.

Its customers are clinicians and facilities in the Advanced Wound Care and surgical markets, including physician offices such as podiatry clinics, wound care centers, hospitals, nursing homes, ambulatory surgery centers and federal facilities such as the VA. Domestic sales account for the vast majority of revenue. The company is expanding internationally, mainly in Japan, where EPIFIX is the first and only approved amniotic tissue product for wound treatment and is sold through distribution partner Gunze Medical. Purchasers generally depend on third-party reimbursement. The company sells through a direct sales force, independent sales agents focused mainly on surgical applications, and distributors.

Placental tissue is donated by consenting mothers through a network of hospitals across the United States, with third-party providers used as needed. The tissue is processed at facilities in Marietta and Kennesaw, Georgia, using the patented PURION process plus terminal sterilization, and the products have a five-year room-temperature shelf life. MIMEDX operates an FDA-registered tissue bank and is an accredited member of the AATB. Its operations are subject to FDA current good tissue practice regulations. The FDA has taken the position that AXIOFILL is not a Section 361 HCT/P and issued a Warning Letter in December 2023, and the company has sued the FDA over this and may keep marketing the product during the proceedings. MIMEDX owns 82 U.S. patents on its amniotic tissue technology and has nearly 300 issued and pending patents globally.